Close menu
Brain & Behavior
Grants & Prizes
Home
Research
Illness
Addiction
Anxiety Disorders
Attention-Deficit Hyperactivity Disorder (ADHD)
Autism Spectrum Disorder (ASD)
Bipolar Disorder
Borderline Personality Disorder (BPD)
Depression
Eating Disorders
Mental Illness (General)
Obsessive-Compulsive Disorder (OCD)
Post-Traumatic Stress Disorder (PTSD)
Schizophrenia
Suicide Prevention
Other Brain-Related Illnesses
Category
Basic Research
New Technologies
Early Intervention/ Diagnostic Tools
Next Generation Therapies
Blog
Get Involved
Give
Donate Today
Make a Memorial/Tribute Gift
Create an Event/Memorial Page
Find an Event/Memorial Page
Make a Stock/Securities Gift/IRA Charitable Rollover Gift
Donate Cryptocurrency
Get Involved
Other Giving Opportunities
Planned Giving
Research Partners
Donor Advised Funds
Workplace Giving
Team Up for Research!
Sponsorship Opportunities
Watch
Healthy Minds TV
Meet the Scientist Webinars
Videos
Connect
Ask the Expert
Join Us
Home
Grants
Grant FAQs
BBRF Young Investigator Grants
BBRF Independent Investigator Grants
BBRF Distinguished Investigator Grants
Prizes & Awards
Klerman & Freedman Prizes
Outstanding Achievement Prizes
Lieber Prize for Schizophrenia Research
Maltz Prize for Schizophrenia Research
Colvin Prize for Mood Disorders Research
Ruane Prize for Child and Adolescent Psychiatric Research
Goldman-Rakic Prize for Cognitive Neuroscience Research
The Pardes Humanitarian Prize
Productive Lives Awards
Blog
About Us
Who We Are
Our Impact
FAQs
Media Center
News
Press Releases
Opinion Pieces
In the News
Multimedia Library
Media Kit
Events & Webinars
Team Up for Research! Events
Healthy Minds TV
Contact
Email Signup
Open Menu

Menu

How long will it take to get real improvements in treatment for illnesses like schizophrenia?

Go Back to the Questions

Q. How long will it take to get real improvements in treatment for illnesses like schizophrenia?

Bryan L. Roth, M.D., Ph.D.
Answer By: Bryan L. Roth, M.D., Ph.D.
Michael J. Hooker Chair of Protein Therapeutics and Translational Proteomics, Distinguished Professor, Department of Pharmacology, School of Medicine, and Division of Medicinal Chemistry and Natural Products, School of Pharmacy
Director, National Institute of Mental Health (NIMH) Psychoactive Drug Screening Program
University of North Carolina Chapel Hill Medical School
There are several novel medications in both early- and later-stage clinical development which hold out hope for new treatment options as well as many in earlier stages of the pipeline. If only one of these proved effective (for example Gly-T I inhibitors currently in Phase III trials), we could expect new options within a couple of years. The early stage medications, coming mainly from pharmaceutical companies, are at least 5 years away. A new pan-NIH-initiative to accelerate drug discovery via academic labs could yield fruit, with a fair amount of luck, within the 5-year timeline.
Tags:
Schizophrenia
Ask an Expert

Related Articles

Researchers Propose a New Understanding of Dopamine's Role in Learning and Memory

READ

Posted: Thursday, September 30, 2021

Researchers Propose a New Understanding of Dopamine's Role in Learning and Memory

Read more
Obesity Is a Risk Factor for Brain-Structure Changes in Schizophrenia and Bipolar Disorder, 2 Studies Show

READ

Posted: Thursday, August 12, 2021

Obesity Is a Risk Factor for Brain-Structure Changes in Schizophrenia and Bipolar Disorder, 2 Studies Show

Read more
Negative Symptoms in Schizophrenia Worsened Under Pandemic Conditions, Study Finds

READ

Posted: Thursday, July 8, 2021

Negative Symptoms in Schizophrenia Worsened Under Pandemic Conditions, Study Finds

Read more
Study Links Schizophrenia Medicines’ Anticholinergic Impact to Risk of Cognitive Impairment

READ

Posted: Thursday, July 1, 2021

Study Links Schizophrenia Medicines’ Anticholinergic Impact to Risk of Cognitive Impairment

Read more